Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Acta Biomaterialia|June 26, 2026
Potential-gradient reprogramming of zinc-based membranes for orthopedic applicationsDan Jiang, Zhang-Zhi Shi, Wei Gou, et al.
Medcomm|July 17, 2024
Detection of minimal hepatic encephalopathy in patients with cirrhosis based on the Stroop-CN model (NCRCID-CHESS 2106): a prospective multicenter studyXiaoyan Li, Shanghao Liu, Ying Guo, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 17, 2025
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled StudyShangzhu Zhang, Dong Xu, Shengyun Liu, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
BMJ Open|July 11, 2024
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in ChinaChuan Liu, Liting Zhang, Shuairan Zhang, et al.
Gut|March 30, 2026
Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetesYuping Chen, Bingtian Dong, Xinrui Jin, et al.
Pageof 6